Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate

References

• Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771–4.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62: 2569–81.
   Google Scholar
• Ministry of Health, Labour and Welfare Study Group. Diagnosis manual and treatment guidelines under the principle of EBM (MHLW Study Group). Tokyo: Japan Rheumatism Foundation; 2004
   Google Scholar
• American College of Rheumatology on Rheumatoid arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328–46.
   PubMedGoogle Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Post-marketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Harigai M. Is the combination of etanercept and methotrexate safe as a means of treating rheumatoid arthritis? Method for analysis of survey data from all etanercept-treated cases. Rheu-matology. 2008;39:21–6.
   Google Scholar
• Yoshio N, Nishimoto N. Criteria for selection among biological preparations. Clin Rheumatol Relat Res. 2008;20:13–8.
   Google Scholar
• Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clini-cal outcomes. Arthritis Rheum. 2002;46:1443–50.
   PubMed Web of Science ®Google Scholar
• Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spec-trum of clinical response in early rheumatoid arthritis. J Rheu-matol. 2009;36:1429–41.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mariette X, Montecucco C, Monteagudo-Sdez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in com-bination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732–9.
   Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of eta-nercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, et al. Etanercept in combination with sulfasalazine, hydroxy-chloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol. 2006;33:213–8.
   PubMed Web of Science ®Google Scholar
• Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis. 2009;68:1146–52.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DA528-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488–92.
   PubMed Web of Science ®Google Scholar
• Never-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW, et al. A double-blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an ear-lier effect of sulphasalazine. Ann Rheum Dis. 1989;48:389–95.
   PubMed Web of Science ®Google Scholar
• Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937–41.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Abe C, Warabi H, Abe S, Kageyama T, Kosaka S, et al. Clinical evaluation of 5A96 on rheumatoid arthritis (in Japanese). ENSHOU. 1985;5:333–43.
   Google Scholar
• Shiokawa Y, Ogawa N, Abe C, Kosaka S, Honma M, Akizuki M, et al. Efficacy official approval of 5A96 on rheumatoid arthritis (in Japanese). I GAKU NO AYUMI. 1985;135:1116.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63–7.
   PubMedGoogle Scholar
• Kameda H, Ueki Y, Saito K, et al. The comparison of efficacy and safety between etanercept (ETN) plus methotrexate (MTX) combination therapy and ETN monotherapy in MTX-refractory Japanese patients with rheumatoid arthritis: 24-week results from JESMR study. Ann Rheum Dis. 2008;67(Suppl II):184.
   Google Scholar
• van Vollenhoven RF, Emestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more effica-cious. Arthritis Res Ther. 2003;5:R347–51.
   Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100–4.
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheuma-toid arthritis. Arch Intern Med. 2008;168:159–66.
   PubMedGoogle Scholar
• Santen Pharmaceutical Co., Ltd. Azulfidine EN tablets-sum-mary of adverse reactions. 5th ed. Osaka: Santen Pharmaceutical Co., Ltd.; 2010
   Google Scholar
• Santen Pharmaceutical Co., Ltd. Rimatil tablets-summary of adverse reactions. 5th ed. Osaka: Santen Pharmaceutical Co., Ltd.; 2010
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.
   PubMed Web of Science ®Google Scholar